ArticleOncology letters2026
Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of CXC motif chemokine ligand 1 (CXCL1) is elevated in numerous types of human cancers, and CXCL1 is also able to act as an autocrine/paracrine factor to accelerate the malignant progression of malignancies. However, at present, there is limited understanding of the role of CXCL1 in renal cell carcinoma (RCC). The present study aimed to investigate the mRNA and protein expression levels of CXCL1 in RCC tissues, which were found to be markedly elevated compared with normal and paracancerous tissues using bioinformatics and immunohistochemical analyses. In addition, high expression of CXCL1 was shown to be closely associated with higher stage, grade, tumor, lymph node and metastasis status of clear cell RCC, as well as with poor prognosis in patients. In addition, the expression level of CXCL1 mRNA was found to be associated with the expression of various tumor-associated genes, including numerous chemokines and their receptors, immune cell recruitment of B cells, CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.